A pilot study to monitor Graves' ophthalmopathy with a combination of pattern-reversal and motion-onset visual evoked potentials.
OBJECTIVE
The aim of this pilot study was to evaluate the efficacy of visual evoked potentials (VEPs) in the monitoring of visual function during a high-dose intravenous steroid pulse therapy and apheresis treatment of severe Graves' ophthalmopathy (GO). PATIENTS AND RESEARCH DESIGN: Nine patients with severe and active GO were treated with high-dose methylprednisolone (1 g day(-1) three times within 1 week, then 0.5 g day(-1) seven times for 2 weeks) combined with plasma filtration (twice a week in weeks 1, 2, 4, 7, and 10). Pattern-reversal and motion-onset VEPs were examined three times, pretreatment, after steroid pulses, and after the last apheresis.


RESULTS
After 10 steroid pulses, the visual acuity was significantly better and the pattern-reversal VEP amplitudes (element size of only 20') had a similar trend for improvement. However, this effect disappeared after 7 weeks when only apheresis treatment was performed. No significant changes in the latencies of any of the tested VEP variants were found in relationship to the treatment.


CONCLUSIONS
Only the observed large intraindividual variability of the VEP parameters between repeated examinations of patients with the shortest duration of GO might be recognized as a marker for functional changes of the visual pathway due to GO. Although this pilot study cannot provide a definite view on the usefulness of the extended set of VEPs in objective monitoring of GO, it seems that the steroid pulse therapy effect is detectable in contrast to the lack of influence by apheresis on the electrophysiological parameters tested.
Department of Pathophysiology, Charles University, Hradec Králové, Czech Republic. szanyi@lfhk.cuni.cz
Jana
J
Szanyi
Jan
J
Kremlacek
Zuzana
Z
Kubova
Jana
J
Langrova
Miroslav
M
Kuba
D000284:Administration, Oral; D000328:Adult; D001781:Blood Component Removal; D003131:Combined Modality Therapy; D019299:Decompression, Surgical; D016903:Drug Monitoring / Q000379:methods; D005074:Evoked Potentials, Visual / Q000502:physiology; D005260:Female; D049970:Graves Ophthalmopathy / Q000188:drug therapy / Q000503:physiopathology* / Q000601:surgery / Q000628:therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007262:Infusions, Intravenous; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D010865:Pilot Projects; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D020551:Pulse Therapy, Drug; D011930:Reaction Time; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects / Q000502:physiology
D016756:Immunoglobulins, Intravenous; D011241:Prednisone; D008775:Methylprednisolone